Literature DB >> 19653063

Neurochemical dementia diagnostics: a simple algorithm for interpretation of the CSF biomarkers.

Piotr Lewczuk1, Rüdiger Zimmermann, Jens Wiltfang, Johannes Kornhuber.   

Abstract

Cerebrospinal fluid (CSF)-based neurochemical dementia diagnostics (NDD) is a well-established diagnostic tool for neurodegenerative disorders, including Alzheimer's disease (AD). However, the direct comparison of the concentrations of the biomarkers between laboratories is often very misleading, due to relatively high inter-laboratory discrepancies of normal/abnormal ranges (cutoff values). Therefore, an interpretation tool might be useful for centers performing NDD to facilitate a standardized, diagnostic-oriented reporting of the data on biomarkers. In this study, we present a simple, easy-to-implement algorithm allowing diagnostic-relevant categorization of patients according to the outcome of the CSF NDD results and, correspondingly, enabling reporting of the data to clinicians in a clear and easy-to-follow form. The algorithm is flexible and cutoff values independent, meaning each laboratory can easily supplement it with the cutoff values and normal/abnormal ranges according to the needs; the only prerequisite is to perform the standard CSF NDD assays (amyloid beta peptides and Tau/pTau).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19653063     DOI: 10.1007/s00702-009-0277-y

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  21 in total

1.  Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease.

Authors:  N Itoh; H Arai; K Urakami; K Ishiguro; H Ohno; H Hampel; K Buerger; J Wiltfang; M Otto; H Kretzschmar; H J Moeller; M Imagawa; H Kohno; K Nakashima; S Kuzuhara; H Sasaki; K Imahori
Journal:  Ann Neurol       Date:  2001-08       Impact factor: 10.422

2.  A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease.

Authors:  N A Verwey; W M van der Flier; K Blennow; C Clark; S Sokolow; P P De Deyn; D Galasko; H Hampel; T Hartmann; E Kapaki; L Lannfelt; P D Mehta; L Parnetti; A Petzold; T Pirttila; L Saleh; A Skinningsrud; J C V Swieten; M M Verbeek; J Wiltfang; S Younkin; P Scheltens; M A Blankenstein
Journal:  Ann Clin Biochem       Date:  2009-04-02       Impact factor: 2.057

3.  Decreased phospholipase A2 activity in cerebrospinal fluid of patients with dementia.

Authors:  Stefan Smesny; Susan Stein; Ingo Willhardt; Jürgen Lasch; Heinrich Sauer
Journal:  J Neural Transm (Vienna)       Date:  2008-06-27       Impact factor: 3.575

Review 4.  Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease". The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group.

Authors: 
Journal:  Neurobiol Aging       Date:  1998 Mar-Apr       Impact factor: 4.673

5.  Combined CSF tau, p-tau181 and amyloid-beta 38/40/42 for diagnosing Alzheimer's disease.

Authors:  Volker Welge; Oliver Fiege; Piotr Lewczuk; Brit Mollenhauer; Hermann Esselmann; Hans-Wolfgang Klafki; Stefanie Wolf; Claudia Trenkwalder; Markus Otto; Johannes Kornhuber; Jens Wiltfang; Mirko Bibl
Journal:  J Neural Transm (Vienna)       Date:  2009-01-14       Impact factor: 3.575

6.  Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease.

Authors:  W J Strittmatter; K H Weisgraber; D Y Huang; L M Dong; G S Salvesen; M Pericak-Vance; D Schmechel; A M Saunders; D Goldgaber; A D Roses
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-01       Impact factor: 11.205

7.  Identification of novel APP/Abeta isoforms in human cerebrospinal fluid.

Authors:  Erik Portelius; Gunnar Brinkmalm; Ai Jun Tran; Henrik Zetterberg; Ann Westman-Brinkmalm; Kaj Blennow
Journal:  Neurodegener Dis       Date:  2009-02-20       Impact factor: 2.977

8.  Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment.

Authors:  Oskar Hansson; Henrik Zetterberg; Eugeen Vanmechelen; Hugo Vanderstichele; Ulf Andreasson; Elisabet Londos; Anders Wallin; Lennart Minthon; Kaj Blennow
Journal:  Neurobiol Aging       Date:  2008-05-19       Impact factor: 4.673

9.  [Sensitivity of neurochemical dementia diagnostics in CSF compared to 99mTc-SPECT in Alzheimer's dementia].

Authors:  M Weih; M Krinninger; R Zimmermann; P Lewczuk; J Svitek; G Schaller; U Degirmenci; T Richter-Schmidinger; J Wiltfang; T Kuwert; J Kornhuber; D Schmidt
Journal:  Fortschr Neurol Psychiatr       Date:  2009-07-06       Impact factor: 0.752

10.  Tau protein phosphorylated at threonine 181 in CSF as a neurochemical biomarker in Alzheimer's disease: original data and review of the literature.

Authors:  Piotr Lewczuk; Hermann Esselmann; Mirko Bibl; Georg Beck; Juan Manuel Maler; Markus Otto; Johannes Kornhuber; Jens Wiltfang
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 2.866

View more
  30 in total

Review 1.  [New biomarkers for Alzheimer's disease in cerebrospinal fluid and blood].

Authors:  Jonathan Vogelgsang; Jens Wiltfang
Journal:  Nervenarzt       Date:  2019-09       Impact factor: 1.214

2.  Increased concentration of the CSF Tau protein and its phosphorylated form in the late juvenile metachromatic leukodystrophy form: a case report.

Authors:  Joanna Tarasiuk; Katarzyna Kapica-Topczewska; Alina Kułakowska; Dorota Halicka; Wiesław Drozdowski; Johannes Kornhuber; Piotr Lewczuk
Journal:  J Neural Transm (Vienna)       Date:  2012-05-24       Impact factor: 3.575

Review 3.  Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease.

Authors:  Kaj Blennow; Bruno Dubois; Anne M Fagan; Piotr Lewczuk; Mony J de Leon; Harald Hampel
Journal:  Alzheimers Dement       Date:  2014-05-03       Impact factor: 21.566

4.  Multidimensional plasma protein separation technique for identification of potential Alzheimer's disease plasma biomarkers: a pilot study.

Authors:  Andreas Wolfram Henkel; Katharina Müller; Piotr Lewczuk; Thorsten Müller; Katrin Marcus; Johannes Kornhuber; Jens Wiltfang
Journal:  J Neural Transm (Vienna)       Date:  2012-03-14       Impact factor: 3.575

5.  Comparison of cerebrospinal fluid levels of tau and Aβ 1-42 in Alzheimer disease and frontotemporal degeneration using 2 analytical platforms.

Authors:  David J Irwin; Corey T McMillan; Jon B Toledo; Steven E Arnold; Leslie M Shaw; Li-San Wang; Vivianna Van Deerlin; Virginia M-Y Lee; John Q Trojanowski; Murray Grossman
Journal:  Arch Neurol       Date:  2012-08

6.  Confirmation rate of blinded (99m)Tc-SPECT compared to neurochemical dementia biomarkers in CSF in patients with Alzheimer disease.

Authors:  Daniela Schmidt; Rüdiger Zimmermann; Piotr Lewczuk; Gerd Schaller; Umüt Degirmenci; Sebastian Kreil; Jens Wiltfang; Torsten Kuwert; Johannes Kornhuber; Markus Weih
Journal:  J Neural Transm (Vienna)       Date:  2010-08-07       Impact factor: 3.575

Review 7.  Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases.

Authors:  Alberto Lleó; Enrica Cavedo; Lucilla Parnetti; Hugo Vanderstichele; Sanna Kaisa Herukka; Niels Andreasen; Roberta Ghidoni; Piotr Lewczuk; Andreas Jeromin; Bengt Winblad; Magda Tsolaki; Barbara Mroczko; Pieter Jelle Visser; Isabel Santana; Per Svenningsson; Kaj Blennow; Dag Aarsland; José Luis Molinuevo; Henrik Zetterberg; Brit Mollenhauer
Journal:  Nat Rev Neurol       Date:  2014-12-16       Impact factor: 42.937

8.  Validation of the Erlangen Score Algorithm for the Prediction of the Development of Dementia due to Alzheimer's Disease in Pre-Dementia Subjects.

Authors:  Piotr Lewczuk; Johannes Kornhuber; Jon B Toledo; John Q Trojanowski; Malgorzata Knapik-Czajka; Oliver Peters; Jens Wiltfang; Leslie M Shaw
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

Review 9.  Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry.

Authors:  Piotr Lewczuk; Peter Riederer; Sid E O'Bryant; Marcel M Verbeek; Bruno Dubois; Pieter Jelle Visser; Kurt A Jellinger; Sebastiaan Engelborghs; Alfredo Ramirez; Lucilla Parnetti; Clifford R Jack; Charlotte E Teunissen; Harald Hampel; Alberto Lleó; Frank Jessen; Lidia Glodzik; Mony J de Leon; Anne M Fagan; José Luis Molinuevo; Willemijn J Jansen; Bengt Winblad; Leslie M Shaw; Ulf Andreasson; Markus Otto; Brit Mollenhauer; Jens Wiltfang; Martin R Turner; Inga Zerr; Ron Handels; Alexander G Thompson; Gunilla Johansson; Natalia Ermann; John Q Trojanowski; Ilker Karaca; Holger Wagner; Patrick Oeckl; Linda van Waalwijk van Doorn; Maria Bjerke; Dimitrios Kapogiannis; H Bea Kuiperij; Lucia Farotti; Yi Li; Brian A Gordon; Stéphane Epelbaum; Stephanie J B Vos; Catharina J M Klijn; William E Van Nostrand; Carolina Minguillon; Matthias Schmitz; Carla Gallo; Andrea Lopez Mato; Florence Thibaut; Simone Lista; Daniel Alcolea; Henrik Zetterberg; Kaj Blennow; Johannes Kornhuber
Journal:  World J Biol Psychiatry       Date:  2017-10-27       Impact factor: 4.132

10.  Cerebrospinal fluid α synuclein concentrations in patients with positive AD biomarkers and extrapyramidal symptoms.

Authors:  Izabela Winkel; Natalia Ermann; Agnieszka Żelwetro; Bożydar Sambor; Barbara Mroczko; Johannes Kornhuber; Bogusław Paradowski; Piotr Lewczuk
Journal:  J Neural Transm (Vienna)       Date:  2021-05-25       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.